Advertisement
Advertisement
RLYB
Rallybio Corporation Common Stock
16.16
USDSponsored
-0.03
-0.19%
Aug 07, 15:59 UTC -4
Closed
Pre-Market
16.27
+0.11
+0.71%
RLYB Earnings Reports
Positive Surprise Ratio
RLYB beat 15 of 20 last estimates.
75%
Next Report
Date of Next Report
--
Estimate for Q-- -- (Revenue/ EPS)
--
/--
Implied change from Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q-- -- (Revenue/ EPS)
--
/--
Rallybio Corporation Common Stock earnings per share and revenue
On May 13, 2026, RLYB reported earnings of -1.46 USD per share (EPS) for Q1 26, missing the estimate of -1.21 USD, resulting in a -20.09% surprise. Revenue reached 212.00 thousand, compared to an expected --, with a 0.00% difference. The market reacted with a +0.21% price change (close before vs. close after earnings).
Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ANI Pharmaceuticals, Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
$2.09
Actual
$2.21
Surprise
+5.69%
Corvus Pharmaceuticals, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-17.36%
CytomX Therapeutics, Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.09
Surprise
-13.78%
Prothena Corporation plc Ordinary Shares
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.39
Actual
-$0.32
Surprise
+19.76%
Entera Bio Ltd. Ordinary Shares
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.08
Actual
-$0.14
Surprise
-71.57%
BioMarin Pharmaceuticals Inc
Report Date
Aug 06, 2026 For Q2 26
Estimate
$0.70
Actual
$1.20
Surprise
+71.04%
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Praxis Precision Medicines, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$3.73
Actual
-$2.87
Surprise
+23.14%
Ligand Pharmaceuticals Inc.
Report Date
Aug 06, 2026 For Q2 26
Estimate
$1.90
Actual
$2.37
Surprise
+24.56%
Trevi Therapeutics, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.11
Surprise
+2.22%
FAQ
What were Rallybio Corporation Common Stock's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, Rallybio Corporation Common Stock reported EPS of -$1.46, missing estimates by -20.09%, and revenue of $212.00K, 0% as expectations.
How did the market react to Rallybio Corporation Common Stock's Q1 2026 earnings?
The stock price moved up 0.21%, changed from $14.00 before the earnings release to $14.03 the day after.
When is Rallybio Corporation Common Stock expected to report next?
The next earning report is scheduled for --.
What are the forecasts for Rallybio Corporation Common Stock's next earnings report?
Based on --
analysts, Rallybio Corporation Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement